Stentys SA

Stentys SA is a medical technology company specializing in innovative solutions for the treatment of coronary artery disease, particularly through its self-expanding stents. Founded in 2006, Stentys SA operates in the medical device sector, focusing on developing solutions for vascular treatments. The company has its headquarters in Paris, France. Under the leadership of CEO Lottin Christophe, Stentys successfully listed on NYSE Euronext Paris in October 2010, raising EUR 22.

7 million through its IPO. The firm has completed a total of 6 deals since inception, with the latest deal occurring on October 22, 2010, when it raised EUR 22. 7 million. Stentys SA specializes in the design and manufacturing of self-expanding stents that are used in the treatment of coronary artery disease.

Their flagship product addresses the need for effective vascular interventions and aims to improve patient outcomes through innovative stent technology. The company emphasizes the development of solutions that adapt to the natural movements of arterial walls, enhancing the effectiveness of coronary procedures. In 2020, Stentys SA reported revenue of EUR 185,594. 4 and an EBITDA loss of EUR 835,613.

5 for the year 2021. Stentys SA aims to continue expanding its product offerings and enter new markets. Following its recent IPO in October 2010, which raised EUR 22. 7 million, the company plans to utilize these funds for research and development of new vascular solutions.

Specific future initiatives include the launch of advanced stent technologies designed for diverse patient needs, with plans to target additional European and Asian markets by 2023.